Pulmonary Health

Data from Almirall, Forest Labs' aclidinium studies on COPD to be presented at ... News-Medical.net Aclidinium bromide is a new, inhaled long-acting antimuscarinic agent currently under review by the FDA for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). The poster discussion titled "Long-Term Efficacy And Safety of ... and more »

Emphysema is a type of chronic obstructive pulmonary disease (COPD) involving damage to the air sacs (alveoli) in the lungs. As a result, your body does not get the ...

Phase 2 Results for EP-101 Positive Drug Discovery & Development Patients with moderate to severe COPD treated with EP-101 after seven days had a clinically meaningful and statistically significant improvement in lung function versus placebo. EP-101 is a proprietary inhalation solution formulation of glycopyrrolate, ... and more »

Hello Emphysema! Emphysema, often called a disease, is actually a mechanical malfunctioning of the lungs caused by an excessive buildup of impurities.

Emphysema Definition. Emphysema is a chronic respiratory disease where there is over-inflation of the air sacs (alveoli) in the lungs, causing a decrease in lung ...

Chronic bronchitis, which involves a long-term cough with mucus. Emphysema, which involves destruction of the lungs over time. Most people with COPD have a ...

Forest and Almirall to Present Aclidinium Bromide Clinical Data at the ... MarketWatch (press release) Aclidinium bromide is a new, inhaled long-acting antimuscarinic agent currently under review by the FDA for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). The poster discussion titled "Long-Term Efficacy And Safety of ... and more »

Information about emphysema causes and risk factors like cigarette smoking, air pollution, asthma, gender, and age. The most common symptom of emphysema is shortness ...

Novartis to present positive phase III GLOW2 study data at 2012 ATS conference pharmabiz.com “The GLOW2 results affirm the potential for once-daily NVA237 to help patients manage their COPD symptoms and improve their quality of life,” said Tim Wright, Head of Development, Novartis Pharmaceuticals. “Novartis is committed to addressing the unmet ... Novartis NVA237 Phase III data showed rapid, sustained improvement in lung ...PharmiWeb.com (press release) Novartis-Vectura COPD boostBusiness Weekly NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International ...PR Newswire (press release) all 7 news articles »

Emphysema usually refers to a long-term, progressive disease of the lungs that primarily causes shortness of breath. Subcutaneous emphysema refers to a condition when ...